International Clinical Trial: A Study to Learn About the Safety of BIIB147 and Its Effects in Adults With Amyotrophic Lateral Sclerosis (ALS)

Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (NCT07855211) titled 'A Study to Learn About the Safety of BIIB147 and Its Effects in Adults With Amyotrophic Lateral Sclerosis (ALS)' on Sept. 28.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).

Primary Sponsor: Biogen

Condition: Amyotrophic Lateral Sclerosis

Intervention: Drug: BIIB147

Recruitment Status: Not recruiting

Phase: Phase 1/Phase 2

Date of First Enrollment: October 22, 2026

Target Sample Size: 69

To know more, visit https://clinicaltrials.gov/st...